<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines continue to grow as single cells on in vitro passage, show an unusually restricted expression of EBV-latent genes and retain a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> biopsy-like cell surface phenotype (group I/II lines); others change to growth in aggregates, show a broader pattern of virus latent gene expression, and develop a cell surface phenotype more characteristic of EBV-transformed LCL (group III lines) </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that the cell surface <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules LFA-1, ICAM-1, and LFA-3 are expressed at very low levels, if at <z:hpo ids='HP_0000001'>all</z:hpo>, on group I/II lines and are coordinately upregulated as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines move towards group III </plain></SENT>
<SENT sid="2" pm="."><plain>The change to growth in aggregates reflects the increasing availability of LFA-1 and ICAM-1, the two ligands whose mutual interaction underlies homotypic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>The low levels of ICAM-1 and LFA-3 on group I/II <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines are also associated with an impaired ability to interact with EBV-specific CTL in the antigen-independent phase of effector/target conjugation </plain></SENT>
<SENT sid="4" pm="."><plain>mAb blocking studies show that the small number of conjugates that are formed with group I/II <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> targets involve the LFA-1/ICAM-1 adhesion pathway but not the LFA-3 pathway; in contrast, both pathways contribute to the efficient conjugate formation shown by group III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or LCL targets </plain></SENT>
<SENT sid="5" pm="."><plain>Earlier work identified one group III line, WW1 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, as unusual since is expressed the full spectrum of EBV-latent proteins yet remained insensitive to lysis by EBV-specific CTL </plain></SENT>
<SENT sid="6" pm="."><plain>Here we show that this line has an anomalous pattern of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule expression with high levels of LFA-1 and ICAM-1 in the absence of detectable LFA-3 </plain></SENT>
<SENT sid="7" pm="."><plain>The WW1 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells form conjugates with EBV-specific CTL through the LFA-1/ICAM-1 pathway, but in the absence of a target LFA-3/effector CD2 interaction these conjugates do not achieve target cell lysis </plain></SENT>
<SENT sid="8" pm="."><plain>This may reflect an important role for target LFA-3 molecules in activating EBV-specific CTL function </plain></SENT>
<SENT sid="9" pm="."><plain>From these in vitro studies, we postulate that downregulation of the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules LFA-3 and ICAM-1 on EBV+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> underlies the ability of the malignant clone to evade EBV-specific T cell surveillance in vivo </plain></SENT>
</text></document>